Drug Combination Details
| General Information of the Combination (ID: C99532) | |||||
|---|---|---|---|---|---|
| Name | Curcumin NP Info | + | Etoposide Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Acute myeloid leukemia
[ICD-11: 2A60]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Biological
Regulation |
Up-regulation | ROS generation | ||||
| In-vitro Model | HL-60 | CVCL_0002 | Adult acute myeloid leukemia | Homo sapiens | ||
| In-vivo Model | 1*106 BNML cells in 0.5 mL of PBS injected into tail vein in male Brown Norway (BN/CrlCmd) rats. | |||||
| Experimental
Result(s) |
Curcumin can increase the antileukemic effect of etoposide through reactive oxygen species in sensitive myeloid leukemia cells, and it is harmless to normal human cells. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Curcumin enhances the cytogenotoxic effect of etoposide in leukemia cells through induction of reactive oxygen species. Drug Des Devel Ther. 2016 Feb 4;10:557-70. | |||
